SCHEMBL1534517

SCHEMBL1534517

COc1c(F)cccc1C(=O)N(C)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.42
CES1 P23141 3/20 0.42
BCHE P06276 1/20 0.42
KRAS P01116 2/20 0.40
KMT2A Q03164 2/20 0.39
NPC1 O15118 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 1/20 0.39
MLYCD O95822 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
RAB9A P51151 2/20 0.38
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
LPAR5 Q9H1C0 1/20 0.37
GPBAR1 Q8TDU6 1/20 0.37
F10 P00742 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4026691 0.85 CES2 (0.55) CES2CES1BCHEKMT2ANPC1
SCHEMBL29898808 0.83 KMT2A (0.54) CES2CES1BCHEKMT2ANPC1
SCHEMBL257659 0.83 KMT2A (0.54) CES2CES1BCHEKMT2ANPC1
SCHEMBL8577211 0.82 RAB9A (0.52) KMT2ANPC1SMN1; SMN2MEN1RAB9A
SCHEMBL1585165 0.82 CYP11B1 (0.48) CES2CES1BCHEKMT2ANPC1
SCHEMBL21401288 0.82 ESR1 (0.55) CES2CES1BCHEKMT2ANPC1
SCHEMBL6269942 0.81 HSD17B10 (0.39) KMT2ANPC1SMN1; SMN2MEN1MLYCD
SCHEMBL8577021 0.81 POLB (0.41) CES2CES1KMT2ANPC1SMN1; SMN2
SCHEMBL13209693 0.81 CES2 (0.42) CES2CES1BCHEKMT2ANPC1
SCHEMBL2100806 0.81 CES2 (0.42) CES2CES1BCHEKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546376-B2 Pharmaceutical compounds ALMAC DISCOVERY LIMITED (GB) 2013-10-01 US disclosed
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2012-09-20 US disclosed
EP-2473495-A1 PHARMACEUTICAL COMPOUNDS Almac Discovery Limited (GB) 2012-07-11 EP disclosed
WO-2011033265-A1 PHARMACEUTICAL COMPOUNDS ALMAC DISCOVERY LIMITED (GB) 2011-03-24 WO disclosed
WO-2007044796-A2 PYRIDAZINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2007-04-19 WO disclosed
WO-2007044796-A2 PYRIDAZINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238541-A1 PHARMACEUTICAL COMPOUNDS PIK3CA, PLK1, MTOR CES2 2676/4885CES1 2532/4885BCHE 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.